MyFinsight
Home
Compare
Blog
About
Maturities of investments
$42,339K
Net cash provided by
investing activities
$37,470K
Canceled cashflow
$4,869K
Net change in cash,
cash equivalents and...
$22,790K
Canceled cashflow
$14,680K
Purchases of investments
$4,842K
Purchases of property and
equipment
$27K
Receivables from
collaboration partners
-$5,985K
Cash received from
government grants
$3,830K
Stock-based compensation
expense
$2,197K
Accrued license fees
$1,725K
Change in fair value of
convertible note
$1,585K
Depreciation expense
$1,277K
Prepaid expenses and
other current assets
-$890K
Interest expense
$875K
Other non-current
liabilities
$434K
Amortization of right-of-use
asset
$281K
Net
amortization/accretion on investment...
-$210K
Loss on disposal of
equipment
-$4K
Proceeds from exercise of
stock options
$238K
Net cash used in
operating activities
-$12,892K
Net cash (used in) /
provided by financing...
-$1,788K
Canceled cashflow
$19,293K
Canceled cashflow
$238K
Net loss
-$23,824K
Payments of deferred
offering costs
$2,026K
Accruals and other
current liabilities
-$3,236K
Accounts payable
-$2,139K
Deferred revenue
-$1,850K
Operating lease
liabilities
-$616K
Other long-term
assets
$520K
Back
Back
Cash Flow
Scribe Therapeutics, Inc. (SCTX)
Scribe Therapeutics, Inc. (SCTX)
source: myfinsight.com